DexCom (NASDAQ:DXCM) Price Target Cut to $525.00

DexCom (NASDAQ:DXCMGet Rating) had its price objective cut by research analysts at Citigroup from $630.00 to $525.00 in a research report issued to clients and investors on Tuesday, The Fly reports. Citigroup’s target price suggests a potential upside of 61.74% from the stock’s previous close.

A number of other analysts have also recently issued reports on the company. Piper Sandler lowered their price objective on DexCom from $725.00 to $480.00 in a research report on Friday, April 29th. StockNews.com started coverage on DexCom in a research report on Thursday, March 31st. They set a “hold” rating on the stock. Bank of America started coverage on DexCom in a research report on Wednesday, March 2nd. They set a “buy” rating on the stock. Raymond James lowered their price objective on DexCom from $538.00 to $486.00 in a research report on Friday, April 29th. Finally, Wells Fargo & Company upgraded DexCom from an “equal weight” rating to an “overweight” rating and set a $575.00 price objective on the stock in a research report on Wednesday, January 19th. One analyst has rated the stock with a sell rating, two have given a hold rating and fifteen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $541.65.

Shares of DXCM stock opened at $324.60 on Tuesday. DexCom has a 12 month low of $302.61 and a 12 month high of $659.45. The firm has a market cap of $31.85 billion, a PE ratio of 156.81, a price-to-earnings-growth ratio of 5.88 and a beta of 1.05. The stock has a 50 day moving average of $443.08 and a 200-day moving average of $483.80. The company has a quick ratio of 4.79, a current ratio of 5.27 and a debt-to-equity ratio of 0.90.

DexCom shares are going to split before the market opens on Friday, June 10th. The 4-1 split was announced on Friday, March 25th. The newly issued shares will be distributed to shareholders after the closing bell on Thursday, June 9th.

DexCom (NASDAQ:DXCMGet Rating) last issued its quarterly earnings results on Thursday, April 28th. The medical device company reported $0.32 EPS for the quarter, missing analysts’ consensus estimates of $0.52 by ($0.20). DexCom had a return on equity of 12.42% and a net margin of 8.23%. The business had revenue of $628.80 million for the quarter, compared to analyst estimates of $623.97 million. During the same quarter last year, the firm earned $0.33 earnings per share. The firm’s quarterly revenue was up 24.5% compared to the same quarter last year. As a group, equities analysts predict that DexCom will post 3.28 EPS for the current fiscal year.

In other news, insider Steven Robert Pacelli sold 250 shares of the stock in a transaction on Wednesday, February 23rd. The stock was sold at an average price of $394.33, for a total transaction of $98,582.50. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Jereme M. Sylvain sold 600 shares of the company’s stock in a transaction on Friday, March 4th. The shares were sold at an average price of $422.94, for a total value of $253,764.00. The disclosure for this sale can be found here. Insiders have sold 4,009 shares of company stock worth $1,783,689 in the last 90 days. Company insiders own 0.41% of the company’s stock.

Several institutional investors and hedge funds have recently modified their holdings of the company. Vanguard Group Inc. lifted its stake in shares of DexCom by 1.3% during the first quarter. Vanguard Group Inc. now owns 10,550,784 shares of the medical device company’s stock valued at $5,397,781,000 after acquiring an additional 140,465 shares during the period. Baillie Gifford & Co. lifted its stake in DexCom by 1.0% in the first quarter. Baillie Gifford & Co. now owns 4,554,293 shares of the medical device company’s stock valued at $2,329,976,000 after buying an additional 45,107 shares during the period. Sands Capital Management LLC lifted its stake in DexCom by 33.9% in the first quarter. Sands Capital Management LLC now owns 4,189,245 shares of the medical device company’s stock valued at $2,143,218,000 after buying an additional 1,060,655 shares during the period. Jennison Associates LLC lifted its stake in DexCom by 83.4% in the first quarter. Jennison Associates LLC now owns 2,600,283 shares of the medical device company’s stock valued at $1,330,305,000 after buying an additional 1,182,632 shares during the period. Finally, Capital Research Global Investors lifted its stake in DexCom by 55.2% in the fourth quarter. Capital Research Global Investors now owns 2,374,545 shares of the medical device company’s stock valued at $1,275,020,000 after buying an additional 844,916 shares during the period. 93.26% of the stock is currently owned by institutional investors and hedge funds.

About DexCom (Get Rating)

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system.

Further Reading

The Fly logo

Analyst Recommendations for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.